Centogene extends partnership with takeda

Cambridge, mass., rostock, germany and berlin, april 14, 2021 (globe newswire) -- centogene n.v. (nasdaq: cntg), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced today that it has extended its partnership with takeda pharmaceutical company limited (tse: 4502/nyse: tak) to diagnose patients with certain genetic disorders.
CNTG Ratings Summary
CNTG Quant Ranking